Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count

Executive Summary

Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved

You may also be interested in...



FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally

FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year

CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class

FDA's second-half surge in approvals made 2008 the agency's best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation

CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class

FDA's second-half surge in approvals made 2008 the agency's best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation

Related Content

UsernamePublicRestriction

Register

PS049178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel